N-(2-Ethylphenyl)carbamic acid (4aS,9aS)-2,4a,9-trimethyl-2,3,4,4a,9,9a-hexahydro[1,2]oxazino[6,5-b]indol-6-yl ester hydrochloride (223585-99-7)

Identification
Name:	N-(2-Ethylphenyl)carbamic acid (4aS,9aS)-2,4a,9-trimethyl-2,3,4,4a,9,9a-hexahydro[1,2]oxazino[6,5-b]indol-6-yl ester hydrochloride
Synonyms:	Ganstigmine hydrochloride;CHF-2819;N-(2-Ethylphenyl)geneserine hydrochloride
CAS:	223585-99-7
Molecular Formula:	C₂₂H₂₈ClN₃O₃
Molecular Weight:	417.93976
Molecular Structure:
Properties
Safety Data

Other Product

Carbamic acid,N-(2-methylphenyl)-,(4aS,9aS)-2,3,4,4a,9,9a-hexahydro-2,4a,9-trimethyl-1,2-oxazino[6,5-b]indol-6-ylester, hydrochloride (1:1)
Carbamic acid,N-(3-methylphenyl)-,(4aS,9aS)-2,3,4,4a,9,9a-hexahydro-2,4a,9-trimethyl-1,2-oxazino[6,5-b]indol-6-ylester, hydrochloride (1:1)
Carbamic acid,N-heptyl-,(4aS,9aS)-2,3,4,4a,9,9a-hexahydro-2,4a,9-trimethyl-1,2-oxazino[6,5-b]indol-6-ylester, hydrochloride (1:1)
1,2-Oxazino[6,5-b]indole,7-bromo-2,3,4,4a,9,9a-hexahydro-2-methyl-4a,9-bis(3-methyl-2-buten-1-yl)-,(4aS,9aS)-
Carbamic acid, heptyl-,(4aS,9aS)-2,3,4,4a,9,9a-hexahydro-2,4a,9-trimethyl-1,2-oxazino[6,5-b]indol-6-ylester (9CI)
L-Glutamic acid, hydrochloride, mixt. with (4aS-cis)-2,3,4,4a,9,9a-hexahydro-2,4a,9-trimethyl-1,2-oxazino(6,5-b)indol-6-yl methylcarbamate mono(2-hydroxybenzoate) and papain
1,2-Oxazino[6,5-b]indol-6-ol,2,3,4,4a,9,9a-hexahydro-2,4a,9-trimethyl-, (4aS,9aS)-
1,2-Oxazino[6,5-b]indol-6-ol,2,3,4,4a,9,9a-hexahydro-2,4a,9-trimethyl-, 6-(N-methylcarbamate), (4aS,9aS)-
1H-Pyrano[3,4-d]oxepin-4-carboxylicacid,9-[2-(3,4-dihydroxyphenyl)ethoxy]-4a,5,6,8,9,9a-hexahydro-1-hydroxy-6-oxo-,2-(3,4-dihydroxyphenyl)ethyl ester, (1R,4aS,9S,9aS)-
1H-Pyrano[3,4-d]oxepin-4-carboxylicacid, 4a,5,6,8,9,9a-hexahydro-1-hydroxy-9-[2-(4-hydroxyphenyl)ethoxy]-6-oxo-,methyl ester, (1R,4aS,9S,9aS)-rel-(+)-
2-Propenoic acid,3-(methylthio)-,(3R,3aR,4S,- 4aS,5R,6S,8aR,9aR)-decahydro-4-methoxy-3,- 4a,5-trimethyl-1-oxo-3a,9a-epoxynaphtho[2,- 3-b]furan-6-yl ester,(2Z)-
(4aS,9aS)-5-amino-8-[(2-methoxy-5-methylphenyl)amino]-6-(trihydroxy-lambda~4~-sulfanyl)-4a,9a-dihydroanthracene-9,10-dione
2-Butenoic acid,2-methyl-,(3S,3aS,4S,4aS,5R,- 6S,8aR,9aS)-decahydro-3,4a,5-trimethyl-6- [[(2Z)-3-(methylthio)-1-oxo-2-propenyl]oxy]- 1-oxo-3a,9a-epoxynaphtho[2,3-b]furan-4-yl ester,(2Z)-
1H-Pyrano[3,4-d]oxepin-4-carboxylicacid, 4a,5,6,8,9,9a-hexahydro-1-hydroxy-9-[2-(4-hydroxyphenyl)ethoxy]-6-oxo-,2-(3,4-dihydroxyphenyl)ethyl ester, (1R,4aS,9S,9aS)-rel-(+)-
salicylic acid, compound with (4aS-cis)-2,3,4,4a,9,9a-hexahydro-2,4a,9-trimethyl-1,2-oxazino[6,5-b]indol-6-yl methylcarbamate (1:1)
5-oxo-L-proline, compound with (4aS-cis)-2,3,4,4a,9,9a-hexahydro-2,4a,9-trimethyl-1,2-oxazino[6,5-b]indol-6-yl methylcarbamate (1:1)
Butanoic acid,3-methyl-,(1aR,3S,4R,4aS,5S,- 9aS)-1a,2,4,4a,5,9-hexahydro-3-hydroxy-4,- 4a,6-trimethyl-3H-oxireno[8,8a]naphtho[2,3-b]- furan-5-yl ester
2-Butenoic acid,2-methyl-,(3R,3aR,3'aS,4S,- 6'R,6'aR,9'R,9aS,9'aS,9bR,9'bS)-2',3',3a,3'a,4,5,- 5',6',7,9',9a,9'a,9b,9'b-tetradecahydro-6'- hydroxy-6,6',9,9'-tetramethyl-3'-methylene-2,- 2',7-trioxospiro[azuleno[4,5-b]furan-3(2H),10'- [4H-6a,9]ethanoazuleno[4,5-b]furan]-4-yl ester,(2Z)-
2-Butenoic acid,2-methyl-,(3S,3aR,3'aS,4S,- 6'R,6'aR,9'R,9aS,9'aS,9bR,9'bS)-2',3',3a,3'a,4,5,- 5',6',7,9',9a,9'a,9b,9'b-tetradecahydro-6'- hydroxy-6,6',9,9'-tetramethyl-3'-methylene-2,- 2',7-trioxospiro[azuleno[4,5-b]furan-3(2H),10'- [4H-6a,9]ethanoazuleno[4,5-b]furan]-4-yl ester,(2Z)-
2-Butenoic acid,2-methyl-,(3S,3aR,3'aS,4S,- 6'R,6'aR,9'R,9aS,9'aS,9bR,9'bS)-2',3',3a,3'a,4,5,- 5',6',7,9',9a,9'a,9b,9'b-tetradecahydro-6'- hydroxy-6,6',9,9'-tetramethyl-3'-methylene-2,- 2',7-trioxospiro[azuleno[4,5-b]furan-3(2H),10'- [4H-6a,9]ethanoazuleno[4,5-b]furan]-4-yl ester,(2E)-